Skip to main content

Search

Show all results for

Home

Person

Dina Hofer

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (4)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

NAD(+) homeostasis in health and disease

Johan Auwerx, Mario Romani, Elena Katsyuba, Dina Hofer

The conceptual evolution of nicotinamide adenine dinucleotide (NAD(+)) from being seen as a simple metabolic cofactor to a pivotal cosubstrate for proteins regulating metabolism and longevity, including the sirtuin family of protein deacylases, has led to ...

2020

Niacin: an old lipid drug in a new NAD(+) dress

Johan Auwerx, Mario Romani, Elena Katsyuba, Dina Hofer

Niacin, the first antidyslipidemic drug, has been at the center stage of lipid research for many decades before the discovery of statins. However, to date, despite its remarkable effects on lipid profiles, the clinical outcomes of niacin treatment on cardi ...

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC2019

Mitochondrial and NAD plus metabolism predict recovery from acute kidney injury in a diverse mouse population

Johan Auwerx, Giacomo Vincenzo Giorgio Von Alvensleben, Maroun Bou Sleiman, Dina Hofer, Yang Li, Alexis Maximilien Bachmann, Jean-David Horacio Morel

Acute kidney failure and chronic kidney disease are global health issues steadily rising in incidence and prevalence. Animal models on a single genetic background have so far failed to recapitulate the clinical presentation of human nephropathies. Here, we ...

AMER SOC CLINICAL INVESTIGATION INC2023